U.S. Markets closed

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.98+0.11 (+0.31%)
At close: 4:00PM EDT
35.98 0.00 (0.00%)
After hours: 04:02PM EDT

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000

Full Time Employees959

Key Executives

NameTitlePayExercisedYear Born
Dr. Stuart W. PeltzCo-Founder, CEO & Exec. Director1.7M45.41M1960
Dr. Allan Steven JacobsonIndependent Co-Founder, Chairman of Scientific Advisory Board & Director140kN/A1946
Ms. Emily Luisa HillChief Financial Officer782.5kN/A1981
Dr. Neil AlmsteadChief Technical Operations Officer797.41k3.38M1967
Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer804.35k1.23M1961
Mr. Eric PauwelsChief Bus. Officer975.14kN/A1962
Ms. Christine UtterSr. VP, Chief Accounting Officer & Head of People ServicesN/AN/A1978
Ms. Ellen Welch Ph.D.Chief Scientific OfficerN/AN/AN/A
Alex KaneInvestor Relations OfficerN/AN/AN/A
Ms. Jane BajVP of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate Governance

PTC Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 6. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.